co.don AG is awarded the US-Patent: Process to produce cell transplants patented successfully

15-Mar-2011 - Germany

co.don AG has announced yet another great achievement. An important patent has been granted recently to the Brandenburg enterprise by the American patent office "United States Patent and Trademark Office". The refined method by co.don AG for growing three-dimensional autologous cell transplants (ACT-3D) is now protected on the US market. Application for a patent was filed back in 2001.

"Being awarded the patent gives us a leading position in technology and know-how in North America," says Dr. Andreas Baltrusch, CEO of co.don AG. The US is one of the largest health care markets worldwide. "The patent application," according to Dr. Baltrusch, "has been an important step towards selling co.don AG products abroad in future."

The US-Patent, with the number 7 887 843 B2, protects the method of growing transplants, the base for the co.don chondrosphere® product. These transplants are used for the treatment of damages to the articular cartilage in knee, hip, ankle, elbow and shoulder joints. For this treatment, healthy articular cartilage cells are removed from the patient, then isolated in the laboratory and by adding the patient's own blood serum, cultivated into a three-dimensional cartilage cell transplant within a few weeks. With a minimally invasive intervention, the autologous transplant is then implanted into the damaged articular cartilage, a gentle method for the patient, which often makes the use of prosthesis superfluous later on.

This patent-protected cell cultivation by co.don AG abstains completely from using antibiotics, growing factors and fungistats (antifungal agents). Furthermore, these products are made without any genetic modification and without alien matrix despite its three-dimensionality.

https://www.bionity.com/en/news/131344/co-don-ag-is-awarded-the-us-patent-process-to-produce-cell-transplants-patented-successfully.html